Clinical evaluation of intramuscular injection of microencapsulated compound megestrol acetate.
A comparative clinical study was undertaken by the Sichuan Cooperative Research Group for Microencapsulated Contraceptives to assess the efficacy of intramuscular microencapsulated megestrol compound as a long-acting contraceptive and to find the optimal dosage as regards efficacy, side effects and menstrual irregularities. Eight hundred twenty eight women were divided into four groups and injected monthly with four different dosage combinations that consisted of megestrol acetate and estradiol valerate. In all, 5298 dosage cycles were observed. The investigation indicated that microencapsulation effectively prolonged contraceptive effect of the short-acting agents, reduced the required dosage and lowered the incidence of side effects. A combination of 15 mg megestrol acetate and 5 mg estradiol valerate, as compared to the other three regimens, was found to be clinically most acceptable because of the lower incidence of menstrual irregularities.
D000328:Adult; D002986:Clinical Trials as Topic; D004339:Drug Compounding; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019290:Megestrol Acetate; D008598:Menstruation / Q000187:drug effects; D011247:Pregnancy; D013997:Time Factors
D004958:Estradiol; D008535:Megestrol; D019290:Megestrol Acetate